There was no significant change in drug susceptibility to CIS between 143B control and WNT5B KO adherent cells or spheres (adherent CIS IC50: 2.0 μM control, 2.1 μM WNT5B KO; sphere CIS IC50: 22.4 μM control, 21.0 μM WNT5B KO) (Figure 5C,D). This evidence concerns the gene WNT5B and in situ carcinoma.